At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time

AMP 2020 Annual Meeting and Expo

From Leo O’Connor of LabPulse.com At the Association for Molecular Pathology annual meeting and exposition this week, Immunexpress launched a rapid molecular diagnostic test that could enable ruling in or ruling out sepsis in one hour. The SeptiCyte Rapid test is different from almost all other sepsis tests on the market by means of its operation directly…

Read More

A multi-site study confirms the use of undiluted EDTA blood for the SeptiCyte RAPID sepsis assay

Cision PR Newswire

Data Validating EDTA Blood as Sample Type for SeptiCyte® RAPID Presented at the Association for Molecular Pathology 2022 Annual Meeting SEATTLE and BRISBANE, Australia, Nov. 3, 2022 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the presentation of an abstract at the Association for Molecular Pathology 2022 Annual Meeting…

Read More

Interview with Dr Rolland Carlson and Dr Richard Brandon

Drug Target Review screenshot

The 2022 Drug Target Review Assays ebook, includes an interview about our sepsis detection initiative. In this collection of articles, Dr. Rolland Carlson and Dr. Richard Brandon, Immunexpress, answer questions about molecular diagnostics and how their biomarker signature discovery approach has aided them in creating an assay for the detection of sepsis. Source: Drug Target…

Read More

Most People Don’t Know What Sepsis Is

September is Sepsis Awareness Month and part of the problem in fighting sepsis is that most people don’t know what it is, reports Westwood One. However, now there may be a faster way to detect it. Sepsis occurs when the body’s efforts to fight an infection trigger inflammation throughout the body. CEO of Immunexpress Rollie…

Read More

European and U.S. Patent Allowances Strengthen Immunexpress’ Leading Position in Host-Response Sepsis Diagnostics

Immunexpress.com

Patent Allowances Relate to SeptiCyte™ Technology Using Biomarkers These allowances further reinforce the claims of the core family of patents that support the Company’s gene expression technology in the detection of host response to sepsis SEATTLE, Sept. 24, 2018 – Immunexpress, Inc., today announced the receipt of ‘Notices of Allowance’ from both the U.S. Patent…

Read More

3 Need-to-Know Leaps in Sepsis Care

Rolland Carlson, PhD, CEO of Immunexpress, discusses a different approach to the sepsis battle. Rather than passively chasing pathogens, the Company has developed a test to measure the body’s specific immune response to infection by examining biomarkers in the patient’s blood.

Read More